These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 33660007)
1. Performance of international prognostic indices in plasmablastic lymphoma: a comparative evaluation. Hertel N; Merz H; Bernd HW; Bernard V; Künstner A; Busch H; von Bubnoff N; Feller AC; Witte HM; Gebauer N J Cancer Res Clin Oncol; 2021 Oct; 147(10):3043-3050. PubMed ID: 33660007 [TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of international prognostic indices in gray-zone lymphoma. Witte HM; Merz H; Bernd HW; Bauer A; Bernard V; Feller AC; Gebauer N Leuk Lymphoma; 2022 Apr; 63(4):894-902. PubMed ID: 34856873 [TBL] [Abstract][Full Text] [Related]
3. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Ruppert AS; Dixon JG; Salles G; Wall A; Cunningham D; Poeschel V; Haioun C; Tilly H; Ghesquieres H; Ziepert M; Flament J; Flowers C; Shi Q; Schmitz N Blood; 2020 Jun; 135(23):2041-2048. PubMed ID: 32232482 [TBL] [Abstract][Full Text] [Related]
4. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients. Troppan KT; Melchardt T; Deutsch A; Schlick K; Stojakovic T; Bullock MD; Reitz D; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Egle A; Pichler M Eur J Haematol; 2015 Dec; 95(6):538-44. PubMed ID: 25677782 [TBL] [Abstract][Full Text] [Related]
5. Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. Han Y; Yang J; Liu P; He X; Zhang C; Zhou S; Zhou L; Qin Y; Song Y; Sun Y; Shi Y Oncologist; 2019 Nov; 24(11):e1251-e1261. PubMed ID: 30952824 [TBL] [Abstract][Full Text] [Related]
6. [The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma]. Song JL; Wei XL; Zhang YK; Hao XX; Huang WM; Wei Q; Wei YQ; Feng R Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):739-744. PubMed ID: 30369184 [No Abstract] [Full Text] [Related]
7. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma. Yang Y; Wang L; Ma Y; Han T; Huang M Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332 [TBL] [Abstract][Full Text] [Related]
8. Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis. Bishton MJ; Hughes S; Richardson F; James E; Bessell E; Sovani V; Ganatra R; Haynes AP; McMillan AK; Fox CP Br J Haematol; 2016 Jan; 172(2):246-54. PubMed ID: 26577576 [TBL] [Abstract][Full Text] [Related]
9. A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy. Hwang HS; Yoon DH; Suh C; Huh J Ann Hematol; 2016 Aug; 95(8):1249-58. PubMed ID: 27167532 [TBL] [Abstract][Full Text] [Related]
10. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Zhou Z; Sehn LH; Rademaker AW; Gordon LI; Lacasce AS; Crosby-Thompson A; Vanderplas A; Zelenetz AD; Abel GA; Rodriguez MA; Nademanee A; Kaminski MS; Czuczman MS; Millenson M; Niland J; Gascoyne RD; Connors JM; Friedberg JW; Winter JN Blood; 2014 Feb; 123(6):837-42. PubMed ID: 24264230 [TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of international prognostic index, revised international prognostic index, enhanced international prognostic index and Grupo Español de Linfomas/trasplante autólogo de médula ósea-international prognostic index for diffuse large B-cell lymphoma]. Feng YX; Su LP Zhonghua Zhong Liu Za Zhi; 2020 Nov; 42(11):949-954. PubMed ID: 33256307 [No Abstract] [Full Text] [Related]
12. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. Vassilakopoulos TP; Michail M; Papageorgiou S; Kourti G; Angelopoulou MK; Panitsas F; Sachanas S; Kalpadakis C; Katodritou E; Leonidopoulou T; Kotsianidis I; Hatzimichael E; Kotsopoulou M; Dimou M; Variamis E; Boutsis D; Terpos E; Dimopoulou MN; Karakatsanis S; Michalis E; Karianakis G; Tsirkinidis P; Vadikolia C; Poziopoulos C; Pigaditou A; Vrakidou E; Economopoulos T; Kyriazopoulou L; Siakantaris MP; Kyrtsonis MC; Symeonidis A; Anargyrou K; Papaioannou M; Hatjiharissi E; Vervessou E; Tsirogianni M; Palassopoulou M; Gainaru G; Stefanoudaki E; Zikos P; Tsirigotis P; Tsourouflis G; Assimakopoulou T; Konstantinidou P; A Papadaki H; Megalakaki K; Dimopoulos MA; Pappa V; Karmiris T; Roussou P; Panayiotidis P; Konstantopoulos K; Pangalis GA Oncologist; 2021 Jul; 26(7):597-609. PubMed ID: 33870594 [TBL] [Abstract][Full Text] [Related]
13. Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma-an analysis of 386 Portuguese patients. Coutinho R; Lobato J; Esteves S; Cabeçadas J; Gomes da Silva M Ann Hematol; 2019 Aug; 98(8):1937-1946. PubMed ID: 30949752 [TBL] [Abstract][Full Text] [Related]
14. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β Montalbán C; Díaz-López A; Dlouhy I; Rovira J; Lopez-Guillermo A; Alonso S; Martín A; Sancho JM; García O; Sánchez JM; Rodríguez M; Novelli S; Salar A; Gutiérrez A; Rodríguez-Salazar MJ; Bastos M; Domínguez JF; Fernández R; Gonzalez de Villambrosia S; Queizan JA; Córdoba R; de Oña R; López-Hernandez A; Freue JM; Garrote H; López L; Martin-Moreno AM; Rodriguez J; Abraira V; García JF; Br J Haematol; 2017 Mar; 176(6):918-928. PubMed ID: 28106247 [TBL] [Abstract][Full Text] [Related]
15. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma. Go SI; Park S; Kim JH; Kim HR; Kim M; Moon K; Seo J; Lee GW Tumori; 2018 Aug; 104(4):292-299. PubMed ID: 29737944 [TBL] [Abstract][Full Text] [Related]
16. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study. Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932 [TBL] [Abstract][Full Text] [Related]
17. Plasmablastic lymphoma - single centre experience with infusional EPOCH chemotherapy. Jayachandran PK; Rajan AK; Karunakaran P; Mehra N; Selvarajan G; Kesana S; Dhanushkodi M; Radhakrishnan V; Sagar TG Leuk Res; 2020 Aug; 95():106391. PubMed ID: 32559556 [TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic features of plasmablastic lymphoma: Single-center series of 8 cases from Saudi Arabia. Elyamany G; Alzahrani AM; Aljuboury M; Mogadem N; Rehan N; Alsuhaibani O; Alabdulaaly A; Al-Mussaed E; Elhag I; AlFiaar A Diagn Pathol; 2015 Jun; 10():78. PubMed ID: 26108914 [TBL] [Abstract][Full Text] [Related]
19. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224 [TBL] [Abstract][Full Text] [Related]
20. Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities. Antic D; Jelicic J; Trajkovic G; Balint MT; Bila J; Markovic O; Petkovic I; Nikolic V; Andjelic B; Djurasinovic V; Sretenovic A; Smiljanic M; Vukovic V; Mihaljevic B Ann Hematol; 2018 Feb; 97(2):267-276. PubMed ID: 29130134 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]